07/01/2025
6:08 AM | Aerovate Therapeutics (Filer)
Jade Biosciences, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2025
4:31 PM | Atlas Venture Associates XII, L.P. (Reporting)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/25/2025
4:37 PM | Atlas Venture Fund XII, L.P. (Reporting)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/24/2025
3:59 PM | Atlas Venture Associates XII, L.P. (Reporting)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/24/2025
4:03 PM | Atlas Venture Fund XII, L.P. (Reporting)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/20/2025
3:23 PM | Deep Track Capital, LP (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
| Form SCHEDULE 13G | |
06/06/2025
9:03 AM | FMR LLC (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
| Form SCHEDULE 13G | |
05/05/2025
8:43 AM | Frazier Life Sciences Public Fund, L.P. (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
| Form SCHEDULE 13G | |
05/01/2025
5:31 PM | Fairmount Funds Management LLC (Filed by)
Aerovate Therapeutics (Subject)
Jade Biosciences, Inc. (Subject)
| Form SCHEDULE 13D | |
05/01/2025
4:44 PM | Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Klein Lawrence Otto (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:51 PM | Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Lavelle Erin (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
Get the Latest News and Ratings for AVTE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
05/01/2025
4:58 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Kiselak Tomas (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
5:00 PM | DOBMEIER ERIC (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
5:07 PM | CAIN CHRISTOPHER W. (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
5:10 PM | Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Klein Lawrence Otto (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
5:15 PM | Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Lavelle Erin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
5:16 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Kiselak Tomas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
4:21 PM | Frohlich Tom (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:22 PM | Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Quick Jonathan (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:27 PM | Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
King Andrew James (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:30 PM | Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
Kocinsky Hetal (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:32 PM | Balta Elizabeth (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:39 PM | DOBMEIER ERIC (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:41 PM | CAIN CHRISTOPHER W. (Reporting)
Aerovate Therapeutics (Issuer)
Jade Biosciences, Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
3:22 PM | Aerovate Therapeutics (Filer)
Jade Biosciences, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/25/2025
3:30 PM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/23/2025
3:37 PM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/21/2025
7:07 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/09/2025
3:20 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
04/09/2025
6:00 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/09/2025
6:01 AM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
04/07/2025
7:39 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/07/2025
7:42 AM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
04/07/2025
7:46 AM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
03/27/2025
6:30 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/26/2025
3:54 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
03/25/2025
11:15 PM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form EFFECT | |
03/25/2025
3:25 PM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 424B3 | |
03/24/2025
9:45 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form S-4/A | |
03/14/2025
4:16 PM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form S-4/A | |
03/03/2025
3:45 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
I was wrong about Trump (Ad) I made a mistake.
A mistake I feel very foolish about.
After speaking with Donald Trump and some of his advisors, I believed him.
I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years.
But I was wrong. Let me show you exactly what we’re doing to prepare. |
02/24/2025
8:57 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form S-4/A | |
01/24/2025
3:17 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
01/22/2025
7:45 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form S-4/A | |
01/13/2025
4:24 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
12/03/2024
5:27 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form S-4
Registration statement under Securities Act of 1933 | |
11/18/2024
4:29 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
10/31/2024
3:55 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
10/31/2024
3:55 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
10/31/2024
3:57 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
10/31/2024
3:57 PM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
10/31/2024
8:27 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
8:29 AM | Aerovate Therapeutics (Subject)
Aerovate Therapeutics, Inc. (Subject)
| Form 425 | |
10/17/2024
3:59 PM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/10/2024
4:04 PM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/12/2024
3:31 PM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/02/2024
5:00 PM | Aerovate Therapeutics (Issuer)
Aerovate Therapeutics, Inc. (Issuer)
Dake Benjamin T (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/08/2024
7:00 AM | Aerovate Therapeutics (Filer)
Aerovate Therapeutics, Inc. (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
